Glucagon-Like Peptide-1 Receptor Agonists are Not Associated with an Increased Risk of Progressing to Vision-Threatening Diabetic Retinopathy
We found no difference in the risk for vision-threatening diabetic retinopathy, nor for its component diseases, DME or PDR, with GLP-1RA use compared to other oral anti-hyperglycemic agents in patients with NPDR.
Authors
- Peter Bracha (ORCID: https://orcid.org/0000-0002-4179-9141)
- Qi N. Cui (ORCID: https://orcid.org/0000-0002-5338-0401)
- Yinxi Yu (ORCID: https://orcid.org/0000-0003-3820-1257)
- Brian L. VanderBeek (ORCID: https://orcid.org/0000-0003-4953-118X)
- Peiying Hua
- Zujaja Tauqeer (ORCID: https://orcid.org/0000-0002-0909-909X)
Institutions
- Penn Presbyterian Medical Center (US)
- Associated Retinal Consultants (US)
- Wolfe Eye Clinic (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- Ophthalmic Epidemiology
- Published
- 2024-10-10
- DOI
- https://doi.org/10.1080/09286586.2024.2399764
- Citations
- 8
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 2.86